{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:15:47Z","timestamp":1772759747820,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jbspin.2016.03.014","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T08:32:31Z","timestamp":1466670751000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study"],"prefix":"10.1016","volume":"84","author":[{"given":"Ariela","family":"Hoxha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Calligaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Di Poi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Favaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Del Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Grava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ravagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Ruffatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.03.014_bib0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12456","article-title":"Safety issues of biologics in pregnant patients with rheumatic diseases","volume":"1317","author":"\u00d8stensen","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0130","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v19.i17.2591","article-title":"Tumor necrosis factor-\u03b1 inhibitor therapy and fetal risk: a systematic literature review","volume":"19","author":"Marchioni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","article-title":"Biologic therapies and pregnancy: the story so far","volume":"53","author":"Hyrich","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0140","first-page":"202","article-title":"Are biologic drugs safe in pregnancy","volume":"64","author":"Calligaro","year":"2014","journal-title":"Reumatismo"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0150","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/kel400","article-title":"Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy","volume":"46","author":"Roux","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0155","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","article-title":"Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register","volume":"70","author":"Verstappen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0170","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4321\/S1130-01082012000200003","article-title":"Is safety infliximb during pregnancy in patients with inflammatory bowel disease?","volume":"104","author":"Arg\u00fcelles-Arias","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0180","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0016-5085(12)60561-7","article-title":"865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy","volume":"146","author":"Mahadevan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0190","first-page":"1014","article-title":"Tumor necrosis factor alpha inhibition and VATER association: a causal relationship","volume":"33","author":"Carter","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0200","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","article-title":"Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum","volume":"68","author":"Murashima","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0205","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","article-title":"Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding","volume":"49","author":"Berthelsen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0210","first-page":"S682","article-title":"Pregnancy outcomes in women exposed to etanercept: OTIS autoimmune diseases in pregnancy project","volume":"58","author":"Johnson","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0215","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1136\/annrheumdis-2014-eular.1996","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from safety surveillance","volume":"73","author":"Clowse","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0220","first-page":"13","article-title":"Births: final data for 2008","volume":"59","author":"Martin","year":"2010","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0225","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.fertnstert.2015.02.009","article-title":"Vanishing twin syndrome: is it associated with adverse perinatal outcome?","volume":"103","author":"Evron","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jbspin.2012.03.004","article-title":"Fertility in male patients with seronegative spondyloarthropathies treated with infliximab","volume":"80","author":"Saougou","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.03.014_bib0240","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16300963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16300963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T02:27:35Z","timestamp":1536632855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X16300963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1297319X16300963"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.03.014","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}